Kyntra Bio halts FG-3246 prostate cancer trial, narrows focus to roxadustatNov 16Quarterly updateFG-3246Kyntra Bio
Kyntra Bio reports Q2 2026 results, reaffirms fourth-quarter trial milestonesAug 13Quarterly updateFG-3246Kyntra Bio